DNAJB4/HLJ1 deficiency sensitizes diethylnitrosamine-induced hepatocarcinogenesis with peritumoral STAT3 activation

Wei-Jia Luo1, Wei-Lun Hsu1, Chih-Yun Lu1

  • 1Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.

Cell Biology and Toxicology
|December 31, 2024
PubMed

Insights

Human Liver DnaJ-Like Protein (HLJ1) deficiency accelerates liver cancer by activating IL-6/STAT3 signaling. Restoring HLJ1 may prevent and treat liver cancer by downregulating this pathway.

Area of Science:

  • Hepatology
  • Oncology
  • Molecular Biology

Background:

  • Environmental toxins and genotoxins contribute to liver cancer development.
  • Cell proliferation in the liver can promote premalignant lesion progression.
  • The function of Human Liver DnaJ-Like Protein (DNAJB4/HLJ1) in liver carcinogenesis is unknown.

Purpose of the Study:

  • To investigate the role of HLJ1 in genotoxin-induced liver carcinogenesis.
  • To explore the molecular mechanisms underlying HLJ1's function in liver cancer.

Main Methods:

  • Whole-genome transcriptomic analysis in HLJ1-deficient mice.
  • Diethylnitrosamine (DEN) administration for short-term and long-term carcinogenicity studies.
  • Cancer cell line transplantation into syngeneic mice.

Main Results:

  • HLJ1 deficiency alters gene expression, activating pathways linked to chemically induced liver cancer and IL-6/STAT3 signaling.
  • HLJ1-deficient mice exhibit amplified STAT3 and H2AX phosphorylation after DEN treatment.
  • HLJ1 deletion promotes tumor proliferation and progression, with STAT3 phosphorylation observed in peritumoral normal tissues.

Conclusions:

  • HLJ1 suppresses liver carcinogenesis by downregulating STAT3 signaling in peritumoral normal cells.
  • HLJ1 deficiency promotes liver cancer development and progression.
  • Enhancing HLJ1 levels could be a therapeutic strategy for liver cancer prevention and treatment.